108 related articles for article (PubMed ID: 92464)
1. E-rosette formation in Graves' ophthalmopathy.
Sergott RC; Felberg NT; Savino PJ; Blizzard JJ; Schatz NJ
Invest Ophthalmol Vis Sci; 1979 Dec; 18(12):1245-51. PubMed ID: 92464
[TBL] [Abstract][Full Text] [Related]
2. Extraocular muscle antibodies and the occurrence of ophthalmopathy in Graves' disease.
de Bellis A; Perrino S; Coronella C; Sansone D; Ruocco G; Tirelli G; Di Martino S; Conte M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
Clin Endocrinol (Oxf); 2004 Jun; 60(6):694-8. PubMed ID: 15163332
[TBL] [Abstract][Full Text] [Related]
3. Graves' ophthalmopathy--immunologic parameters related to corticosteroid therapy.
Sergott RC; Felberg NT; Savino PJ; Blizzard JJ; Schatz NJ
Invest Ophthalmol Vis Sci; 1981 Feb; 20(2):173-82. PubMed ID: 6970185
[TBL] [Abstract][Full Text] [Related]
4. Increase of peripheral B lymphocytes in Graves' disease.
Mori H; Amino N; Iwatani Y; Kabutomori O; Asari S; Motoi S; Miyai K; Kumahara Y
Clin Exp Immunol; 1980 Oct; 42(1):33-40. PubMed ID: 6970099
[TBL] [Abstract][Full Text] [Related]
5. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R
Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908
[TBL] [Abstract][Full Text] [Related]
6. [Titers of antibodies against thyroid membrane antigens in patients with Graves-Basedow disease and progressive infiltrative ophthalmopathy during treatment with glucocorticoids and retro-orbital tissue irradiation].
Pilarska K; Syrenicz A; Czekalski S; Gołebiowska I; Andrzejewska W; Krzystolik Z
Pol Tyg Lek; 1991 Oct 28-Nov 4; 46(43-44):824-6. PubMed ID: 1669170
[TBL] [Abstract][Full Text] [Related]
7. Association of HLA antigen BW35 with severe Graves' ophthalmopathy.
Sergott RC; Felberg NT; Savino PJ; Blizzard JJ; Schatz NJ; Sanford CA
Invest Ophthalmol Vis Sci; 1983 Jan; 24(1):124-7. PubMed ID: 6600737
[TBL] [Abstract][Full Text] [Related]
8. Detectable serum IgE levels in Graves' ophthalmopathy.
Molnár I; Horváth S; Balázs C
Eur J Med Res; 1996 Sep; 1(11):543-6. PubMed ID: 9438158
[TBL] [Abstract][Full Text] [Related]
9. Serum IL-18 levels are not increased in patients with untreated Graves' ophthalmopathy.
Wakelkamp IM; Prummel MF; Wiersinga WM
Horm Metab Res; 2004 Jan; 36(1):44-7. PubMed ID: 14983406
[TBL] [Abstract][Full Text] [Related]
10. Peripheral parameters of oxidative stress in patients with infiltrative Graves' ophthalmopathy treated with corticosteroids.
Bednarek J; Wysocki H; Sowiński J
Immunol Lett; 2004 May; 93(2-3):227-32. PubMed ID: 15158621
[TBL] [Abstract][Full Text] [Related]
11. Thyroid autoantibody profiles in ophthalmic dominant and thyroid dominant Graves' disease differ and suggest ophthalmopathy is a multiantigenic disease.
Goh SY; Ho SC; Seah LL; Fong KS; Khoo DH
Clin Endocrinol (Oxf); 2004 May; 60(5):600-7. PubMed ID: 15104563
[TBL] [Abstract][Full Text] [Related]
12. Graves' ophthalmopathy--a clinical review.
Carter JN
Aust N Z J Ophthalmol; 1990 Aug; 18(3):239-42. PubMed ID: 2261168
[TBL] [Abstract][Full Text] [Related]
13. The relationship between anti-human eye muscle antibodies and thyroid function, anti-TSH receptor antibodies and eye symptoms in Graves' ophthalmopathy.
Molnár I; Balázs C
Wien Klin Wochenschr; 1992; 104(24):744-7. PubMed ID: 1363165
[TBL] [Abstract][Full Text] [Related]
14. Immunologically mediated cytotoxicity against human eye muscle cells in Graves' ophthalmopathy.
Wang PW; Hiromatsu Y; Laryea E; Wosu L; How J; Wall JR
J Clin Endocrinol Metab; 1986 Aug; 63(2):316-22. PubMed ID: 3755139
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood T lymphocyte sensitisation against calsequestrin and flavoprotein in patients with Graves' ophthalmopathy.
Nguyen B; Gopinath B; Tani J; Wescombe L; Wall JR
Autoimmunity; 2008 Aug; 41(5):372-6. PubMed ID: 18568642
[TBL] [Abstract][Full Text] [Related]
16. [The effect of one-month antithyroid therapy on peripheral metabolism of reactive oxygen species in Graves' disease with infiltrative ophthalmopathy].
Bednarek J; Wysocki H; Sowiński J
Przegl Lek; 2004; 61(8):841-4. PubMed ID: 15789912
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
[TBL] [Abstract][Full Text] [Related]
18. Comparative study on IgG and IgA antibodies against human thyroid and eye-muscle antigens in Graves' ophthalmopathy.
Molnár I; Balázs C
Acta Med Hung; 1991; 48(1-2):13-21. PubMed ID: 1813853
[TBL] [Abstract][Full Text] [Related]
19. Determination of urinary mucopolysaccharides in Graves' disease.
Ursu H; Dumitrescu C; Bartoc R; Dumitriu L
Endocrinologie; 1984; 22(4):277-82. PubMed ID: 6240765
[TBL] [Abstract][Full Text] [Related]
20. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
Molnár I
Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
